Follow
Juan Carlos A Adansa Klain
Juan Carlos A Adansa Klain
Investigador asociado, Instituto de Investigación Biomédica de Salamanca
No verified email
Title
Cited by
Cited by
Year
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
The Lancet 381, 805-816, 2012
2425*2012
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer
JJCHSHNCCGT R. Hitt, J. J. Grau, A. López-Pousa, A. Berrocal, C. García ...
Annals of Oncology 25 (1), 216-225, 2013
358*2013
Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study
INCESGINCEU Ruth Pettengell,Matthias Schwenkglenks, Robert Leonard, André ...
Supportive Care in Cancer 16 (11), 1299-1309, 2008
1512008
Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study
MSINCESGINCEU Ruth Pettengell, Andre´ Bosly, Thomas D. Szucs, Christian ...
British Journal of Haematology 144 (5), 677–685, 2008
116*2008
Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
Y Escobar, G Cajaraville, JA Virizuela, R Álvarez, A Muñoz, O Olariaga, ...
Supportive Care in Cancer 23, 2833-2840, 2015
932015
Evaluation of multiparameter flow cytometry for the detection of breast cancer tumor cells in blood samples
I Cruz, J Ciudad, JJ Cruz, M Ramos, A Gómez-Alonso, JC Adansa, ...
American journal of clinical pathology 123 (1), 66-74, 2005
922005
Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study
RL Matthias Schwenkglenks, Ruth Pettengell, Christian Jackisch, Robert ...
Supportive Care in Cancer 19 (4), 483–490, 2010
75*2010
Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment
J Martinez-Trufero, D Isla, JC Adansa, A Irigoyen, R Hitt, I Gil-Arnaiz, ...
British journal of cancer 102 (12), 1687-1691, 2010
652010
Epidemiological characteristics of a Spanish cohort of patients diagnosed with squamous cell carcinoma of head and neck: distribution of risk factors by tumor location
R Seijas-Tamayo, J Fernández-Mateos, JC Adansa Klain, R Mesía, ...
Clinical and Translational Oncology 18, 1114-1122, 2016
322016
Analysis of autophagy gene polymorphisms in Spanish patients with head and neck squamous cell carcinoma
J Fernández-Mateos, R Seijas-Tamayo, JCA Klain, MP Borgoñón, ...
Scientific reports 7 (1), 6887, 2017
262017
Genetic susceptibility in head and neck squamous cell carcinoma in a Spanish population
J Fernández-Mateos, R Seijas-Tamayo, JC Adansa Klain, ...
Cancers 11 (4), 493, 2019
232019
Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a …
J Fernández-Mateos, R Seijas-Tamayo, R Mesía, M Taberna, ...
Oral oncology 63, 38-43, 2016
232016
Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study
E del Barco Morillo, R Mesía, JCA Klain, SV Fernández, J Martínez-Galán, ...
Oral Oncology 62, 54-59, 2016
172016
Oncogenic driver mutations predict outcome in a cohort of head and neck squamous cell carcinoma (HNSCC) patients within a clinical trial
J Fernández-Mateos, J Perez-Garcia, R Seijas-Tamayo, R Mesía, ...
Scientific RepoRtS 10 (1), 16634, 2020
142020
Phase II study of capecitabine as palliative treatment for patients (p) with squamous head and neck cancer (HNC) with locoregional and/or metastatic relapse after previous …
J Martinez-Trufero, D Isla, JC Adansa, A Irigoyen, R Hitt, J Lambea, ...
Journal of Clinical Oncology 27 (15_suppl), 6047-6047, 2009
102009
Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer …
J Martínez-Trufero, A Lozano Borbalas, I Pajares Bernad, ...
Clinical and Translational Oncology 23, 1666-1677, 2021
72021
Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study
EDB Morillo, R Mesía, JCA Klain, SV Fernández, J Martínez-Galán, ...
Oral oncology 62, 54-59, 2016
52016
Spanish Head and Neck Cancer Cooperative Group (TTCC). Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally …
J Fernández-Mateos, R Seijas-Tamayo, R Mesía, M Taberna, ...
Oral Oncol 63, 38-43, 2016
52016
Induction Chemotherapy (Ict) with Docetaxel/Cisplatin/5-Fluorouracil (T/P/F) Followed By Chemoradiotherapy with Cisplatin (Crtp) Vs Bioradiotherapy with Cetuximab (Rtcx) for …
R Hitt, R Mesia, JJ Grau, J Rubió, J Martínez-Trufero, EDB Morillo, ...
Annals of Oncology 25, iv355, 2014
22014
2802 Phase II study of first-line paclitaxel (PTX) with panitumumab (P) in patients with metastatic or recurrent head and neck cancer: TTCC-2009-03 study
EDB Morillo, R Mesia, JCA Klain, SV Fernández, JM Galan, ...
European Journal of Cancer 3 (51), S558, 2015
12015
The system can't perform the operation now. Try again later.
Articles 1–20